SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
暂无分享,去创建一个
A. Addeo | M. Joerger | S. Rothschild | A. Friedlaender | M. Pless | L. Wannesson | P. Froesch | M. Früh | W. Janthur | Y. Metaxas | M. Mark | M. Schwitter | M. Schneider | E. Eboulet | H. Burmeister | Nathalie Baudoux | Susanne Weindler | C. Biaggi-Rudolf